B7-33

Product Overview

A fundamental standard in cardiovascular and tissue remodeling research dictates that exploring advanced antifibrotic compounds requires complete structural integrity and verified chemical purity. The B7-33 formulation addresses these demanding benchmarks, serving as a highly purified synthetic peptide derivative engineered for precise in vitro and in vivo laboratory modeling of relaxin receptor dynamics. Each vial provides pure B7-33, stabilized as a vacuum freeze-dried (lyophilized) powder maintaining a verified purity profile of greater than 98%.

B7-33 is a functionally selective, single-chain synthetic peptide derived from the B-chain of human gene-2 relaxin (H2 relaxin). Unlike native H2 relaxin, which features a complex, dual-chain structure linked by disulfide bonds, B7-33 is a truncated, single-chain peptide containing the essential receptor-binding cassette. This engineered structural modification is a major asset: it simplifies the molecular architecture, significantly lowering manufacturing complexity while preserving the precise binding topology required to selectively activate target pathways.

Operating as a potent, non-promiscuous agonist, B7-33 binds preferentially to the Relaxin Family Peptide Receptor 1 (RXFP1). Upon binding, it activates beneficial pERK1/2 signaling cascades that drive matrix metalloproteinase (MMP) up-regulation and suppress pro-fibrotic transforming growth factor-beta (TGF-β) pathways. Crucially, B7-33 does not activate the cAMP-dependent signaling pathways associated with tumor growth or cross-react with insulin receptors. Documented research demonstrates that this selective mechanism effectively reduces collagen deposition, halts aberrant tissue remodeling, and promotes the breakdown of existing scar tissue. This provides researchers with a highly sophisticated model for investigating targeted organ fibrosis mitigation, vascular compliance, and wound healing dynamics within controlled environments.

Product Specifications

• Form: Lyophilized (vacuum freeze-dried) powder
• Purity: Greater than 98% (verified by HPLC analysis)
• Peptide Architecture: Single-chain synthetic relaxin-like peptide
• Primary Target: RXFP1 (Relaxin Family Peptide Receptor 1)
• Primary Research Focus: Selective Antifibrotic Signaling, MMP Activation, and Tissue Remodeling

Container Specifications

The physical attributes of the storage vessel directly impact the shelf life of the compound. All research environments should utilize clean, chemically inert containers. Glass vials provide the highest level of protection against gas permeability and chemical interaction, though high-density polypropylene tubes serve as a valid alternative. Keep all stored peptides away from automatic frost-free freezers, as their internal defrost cycles create regular temperature swings that compromise peptide longevity.